Moreover, other signaling pathways (e.g., PD-L1 expression and PD-1 checkpoint pathway in cancer, Proteoglycans in cancer, and JAK-STAT signaling pathway) predicted by network pharmacology might also be involved in the anti-NSCLC effect of HMMCR, which needs further verification. This evidence concerns the gene SOAT1 and cancer.